Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781727 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT02781727: Completed Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
NCT02781727 is a Phase 3 study that has completed, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 162 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02781727, a Phase 3 study, has completed, sponsored by Ascendis Pharma Endocrinology Division A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.
Primary Outcome
Annualized height velocity (AHV) at 52 weeks for weekly lonapegsomatropin (TransCon hGH) and daily hGH treatment groups
Interventions
- DRUG Once weekly subcutaneous injection of TransCon hGH
- DRUG Once daily subcutaneous injection of Genotropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 3 |
What the finished NCT02781727 record still lists
NCT02781727 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Once weekly subcutaneous injection of TransCon hGH is the first listed.
NCT02781727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02781727 about?
NCT02781727 is a clinical study titled "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)". A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be include...
What is the current status of trial NCT02781727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2016-12-13. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT02781727?
The interventions under investigation include: Once weekly subcutaneous injection of TransCon hGH (DRUG), Once daily subcutaneous injection of Genotropin (DRUG).
Who is sponsoring clinical trial NCT02781727?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02781727's enrollment target sits among peer trials
162 1474th of 2000 higher than 523 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI